Johnson & Johnson (NYSE:JNJ) Shares Up 1.3% - Here's What Happened

Key Points

• Johnson & Johnson shares rose 1.3% on Friday, trading as high as $235.50 after a recent close of $231.73, even as volume came in below average.
• Positive business catalysts included China approval for nipocalimab, a new MedTech catheter launch, and a collaboration to build a global intelligent operating room network with Abu Dhabi’s health department.
• Wall Street remains constructive on J&J: several analysts raised price targets, the company beat quarterly EPS and revenue estimates, and it increased its quarterly dividend to $1.34 per share.

Johnson & Johnson (NYSE:JNJ - Get Free Report) shot up 1.3% during trading on Friday . The stock traded as high as $235.50 and last traded at $234.6730. 5,460,502 shares were traded during mid-day trading, a decline of 35% from the average session volume of 8,408,575 shares. The stock had previously closed at $231.73.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: J&J received approval in China for nipocalimab, a key pipeline win that expands the drug’s commercial potential and adds to the company’s growth outlook. Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: Analysts highlighted J&J’s diversified pharma and MedTech businesses, pipeline progress, and stronger 2026 outlook as reasons it appears better positioned than Pfizer amid patent risk concerns. J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
• Positive Sentiment: The company unveiled its Shockwave C2 Aero Coronary IVL Catheter, supporting its MedTech growth story in the large coronary artery disease market. Johnson & Johnson (JNJ) Unveils Next‑Gen Catheter for Coronary Artery Disease
• Positive Sentiment: J&J also announced a collaboration to build a global intelligent operating room network with Abu Dhabi’s Department of Health, which could strengthen its surgery and digital-health positioning over time. Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi
• Neutral Sentiment: Recent articles on J&J’s defensive-growth profile and dividend appeal reinforce its image as a reliable blue chip, but they are not major new catalysts for the stock. Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Negative Sentiment: ImmunityBio’s presentation on ANKTIVA versus J&J’s TAR-200 introduces competitive pressure in bladder cancer, though the news is still early and may not materially change J&J’s near-term fundamentals. IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Stifel Nicolaus lifted their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a "hold" rating in a research report on Wednesday, April 15th. Argus lifted their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a "buy" rating in a research report on Thursday, April 16th. Citigroup lifted their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a research report on Tuesday, April 7th. The Goldman Sachs Group lifted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a "buy" rating in a research report on Wednesday, April 15th. Finally, Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $253.04.

Johnson & Johnson Price Performance

The company has a market capitalization of $564.91 billion, a P/E ratio of 27.13, a P/E/G ratio of 2.25 and a beta of 0.27. The business's 50-day simple moving average is $234.19 and its 200 day simple moving average is $223.20. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the previous year, the firm earned $2.77 EPS. Johnson & Johnson's revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a dividend of $1.34 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date is Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. Johnson & Johnson's payout ratio is presently 61.97%.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the last quarter. United Bank increased its position in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company's stock worth $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC increased its position in shares of Johnson & Johnson by 13.4% in the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock worth $896,000 after acquiring an additional 692 shares in the last quarter. Wealth Group Ltd. increased its position in shares of Johnson & Johnson by 12.8% in the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after acquiring an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. increased its position in shares of Johnson & Johnson by 9.8% in the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after acquiring an additional 6,584 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.